ISSN 0300-9092 (Print)
ISSN 2412-5679 (Online)

Российские критерии приемлемости назначения менопаузальной гормональной терапии пациенткам с сердечно-сосудистыми и метаболическими заболеваниями. Согласительный документ Российского кардиологического общества, Российского общества акушеров-гинекологов, Российской ассоциации эндокринологов, Евразийской ассоциации терапевтов, Ассоциации флебологов России, Российского научного медицинского общества терапевтов, Российской ассоциации геронтологов и гериатров, Российского общества специалистов по гинекологической эндокринологии и менопаузе

Шляхто Е.В., Дедов И.И., Серов В.Н., Сухих Г.Т., Арутюнов Г.П., Сучков И.А., Драпкина О.М., Ткачева О.Н., Орлова Я.А., Андреева Е.Н., Юренева С.В., Ярмолинская М.И., Сметник А.А., Виллевальде С.В., Козиолова Н.А., Сергиенко И.В., Явелов И.С., Игрюга О.Б., Григорян О.Р., Дудинская Е.Н., Золотухин И.А., Илюхин Е.А., Аганезова Н.В., Абашова Е.И., Алиева А.С., Арутюнов А.Г., Артымук Н.В., Бабенко А.Ю., Балан В.Е., Баранов И.И., Баранова Е.И., Беженарь В.Ф., Бобров С.А., Габидуллина Р.И., Глезер М.Г., Григорьева Н.Ю., Губарева И.В., Густоварова Т.А., Дженина О.В., Доброхотова Ю.Э., Дубровина С.О., Енькова Е.В., Ермакова Е.И., Зырянов С.К., Каткова Н.Ю., Карахалис Л.Ю., Кирсанова Т.В., Кузнецова Т.Ю., Макаренко Т.А., Мальцева Л.И., Мальчикова С.В., Недогода С.В., Никулина С.Ю., Обоскалова Т.А., Петрова М.М., Плисюк А.Г., Подзолков В.И., Подзолкова Н.М., Протасова А.Э., Савельева И.В., Сандакова Е.А., Сахаутдинова И.В., Селихова М.С., Соколова Т.М., Сотникова Л.С., Спиридонова Н.В., Тапильская Н.И., Тарловская Е.И., Фомин И.В., Хамошина М.Б., Чесникова А.И., Чумакова Г.А., Шапошник И.И., Шереметьева Е.В., Ших Е.В.

Согласительный документ Российского кардиологического общества, Российского общества акушеров-гинекологов, Российской ассоциации эндокринологов, Евразийской ассоциации терапевтов, Ассоциации флебологов России, Российского научного медицинского общества терапевтов, Российской ассоциации геронтологов и гериатров, Российского общества специалистов по гинекологической эндокринологии и менопаузе 

Сопредседатели: Шляхто Е.В., Дедов И.И., Серов В.Н., Сухих Г.Т., Арутюнов Г.П., Сучков И.А., Драпкина О.М., Ткачева О.Н.
Ответственный секретарь рабочей группы: Орлова Я.А.
Рабочая группа: Андреева Е.Н., Юренева С.В., Ярмолинская М.И., Сметник А.А., Виллевальде С.В., Козиолова Н.А., Сергиенко И.В., Явелов И.С., Игрюга О.Б., Григорян О.Р., Дудинская Е.Н., Золотухин И.А., Илюхин Е.А. 
Эксперты: Аганезова Н.В., Абашова Е.И., Алиева А.С., Арутюнов А.Г., Артымук Н.В., Бабенко А.Ю., Балан В.Е., Баранов И.И., Баранова Е.И., Беженарь В.Ф., Бобров С.А., Габидуллина Р.И., Глезер М.Г., Григорьева Н.Ю., Губарева И.В., Густоварова Т.А., Дженина О.В., Доброхотова Ю.Э., Дубровина С.О., Енькова Е.В., Ермакова Е.И., Зырянов С.К., Каткова Н.Ю., Карахалис Л.Ю., Кирсанова Т.В., Кузнецова Т.Ю., Макаренко Т.А., Мальцева Л.И., Мальчикова С.В., Недогода С.В., Никулина С.Ю., Обоскалова Т.А., Петрова М.М., Плисюк А.Г., Подзолков В.И., Подзолкова Н.М., Протасова А.Э., Савельева И.В., Сандакова Е.А., Сахаутдинова И.В., Селихова М.С., Соколова Т.М., Сотникова Л.С., Спиридонова Н.В., Тапильская Н.И., Тарловская Е.И., Фомин И.В., Хамошина М.Б., Чесникова А.И., Чумакова Г.А., Шапошник И.И., Шереметьева Е.В., Ших Е.В.

Для цитирования: Шляхто Е.В., Дедов И.И., Серов В.Н., Сухих Г.Т., Арутюнов Г.П., Сучков И.А., Драпкина О.М., Ткачева О.Н. и др. Российские критерии приемлемости назначения менопаузальной гормональной терапии пациенткам с сердечно-сосудистыми и метаболическими заболеваниями. Согласительный документ Российского кардиологического общества, Российского общества
акушеров-гинекологов, Российской ассоциации эндокринологов, Евразийской ассоциации терапевтов, Ассоциации флебологов России, Российского научного медицинского общества терапевтов, 
Российской ассоциации геронтологов и гериатров, Российского общества
специалистов по гинекологической эндокринологии и менопаузе.
Акушерство и гинекология. 2025; 10: 193-221 
https://dx.doi.org/10.18565/aig.2025.308

Список литературы

  1. Распоряжение Правительства Российской Федерации от 29 декабря 2022 г. N 4356-р «Об утверждении Национальной стратегии действий в интересах женщин на 2023–2030 годы». Доступно по: https://www.consultant.ru/document/cons_doc_LAW_436691. 
  2. Улумбекова Г.Э., Худова И.Ю. Оценка демографического, социального и экономического эффекта при приеме менопаузальной гормональной терапии. ОРГЗДРАВ: новости, мнения. Вестник ВШОУЗ. 2020; 6(4): 23-53. 
  3. Lambrinoudaki I., Armeni E., Goulis D., Bretz S., Ceausu I., Durmusoglu F. et al. Menopause, wellbeing and health: A care pathway from the European Menopause and Andropause Society. Maturitas. 2022; 163: 1-14. https://doi.org/10.1016/j.maturitas.2022.04.008
  4. Министерство здравоохранения Российской Федерации. Клинические рекомендации. Менопауза и климактерическое состояние у женщины. 2025. Доступно по: https://cr.minzdrav.gov.ru/recomend/117_3 
  5. Harlow S.D., Gass M., Hall J.E., Lobo R., Maki P., Rebar R.W. et al.; STRAW 10 Collaborative Group. Executive summary of the Stages of Reproductive Aging Workshop + 10: addressing the unfinished agenda of staging reproductive aging. Menopause. 2012; 19(4): 387-95. https://doi.org/10.1097/ gme.0b013e31824d8f40
  6. Drewe J., Bucher K.A., Zahner C. A systematic review of non-hormonal treatments of vasomotor symptoms in climacteric and cancer patients. Springerplus. 2015; 4: 65. https://doi.org/10.1186/s40064-015-0808-y
  7. Schnatz P.F., Romegialli A., Abrantes J., Marakovits K., Cunningham D., O’Sullivan D.M. The North American Menopause Society: from abstract to publication. Menopause. 2008; 15(5): 996-1001. https://doi.org/10.1097/gme.0b013e318166f026
  8. Paramsothy P., Harlow S.D., Nan B., Greendale G.A., Santoro N., Crawford S.L. et al. Duration of the menopausal transition is longer in women with young age at onset: the multiethnic Study of Women’s Health Across the Nation. Menopause. 2017; 24(2): 142-9. https://doi.org/10.1097/ GME.0000000000000736
  9. Сухих Г.Т., Сметник В.П., Андреева Е.Н., Балан В.Е., Гависова А.А., Григорян О.Р. и др. Менопаузальная гормонотерапия и сохранение здоровья женщин в зрелом возрасте. Клинические рекомендации. 2015: 8-9. Доступно по: https://www.consultant.ru/document/cons_doc_LAW_320073/
  10. Schoenaker D.A., Jackson C.A., Rowlands J.V., Mishra G.D. Socioeconomic position, lifestyle factors and age at natural menopause: a systematic review and meta-analyses of studies across six continents. Int. J. Epidemiol. 2014; 43(5): 1542-62. https://doi.org/10.1093/ije/dyu094
  11. Freeman E.W., Sammel M.D., Sanders R.J. Risk of long-term hot flashes after natural menopause: evidence from the Penn Ovarian Aging Study cohort. Menopause. 2014; 21(9): 924-32. https://doi.org/10.1097/ GME.0000000000000196
  12. Costanian C., Zangiabadi S., Bahous S.A., Deonandan R., Tamim H. Reviewing the evidence on vasomotor symptoms: the role of traditional and non-traditional factors. Climacteric. 2020; 23(3): 213-23. https://doi.org/10.1080/13697137.2019.1711051
  13. Prior J.C. Progesterone for symptomatic perimenopause treatment - Progesterone politics, physiology and potential for perimenopause. Facts Views Vis Obgyn. 2011; 3(2): 109-20.
  14. Santoro N., Epperson C.N., Mathews S.B. Menopausal symptoms and their management. Endocrinol. Metab. Clin. North Am. 2015; 44(3): 497-515. https://doi.org/10.1016/j. ecl.2015.05.001
  15. Мельниченко Г.А., Белая Ж.Е., Рожинская Л.Я., Торопцова Н.В., Алексеева Л.И., Бирюкова Е.В. и др. Федеральные клинические рекомендации по диагностике, лечению и профилактике остеопороза. Проблемы эндокринологии. 2017; 63(6): 392-426. 
  16. Muka T., Oliver-Williams C., Colpani V., Kunutsor S., Chowdhury S., Chowdhury R. et al. Association of vasomotor and other menopausal symptoms with risk of cardiovascular disease: a systematic review and meta-analysis. PLOS One. 2016; 11(6): e0157417. https://doi.org/10.1371/journal.pone.0157417
  17. Baber R.J., Panay N., Fenton A.; IMS Writing Group. 2016 IMS Recommendations on women’s midlife health and menopause hormone therapy. Climacteric. 2016; 19(2): 109-50. https://doi.org/10.3109/13697137.2015.1129166
  18. Kaufman M.R., Ackerman A.L., Amin K.A., Coffey M., Danan E., Faubion S.S. et al. The AUA/SUFU/AUGS Guideline on Genitourinary Syndrome of Menopause. J. Urol. 2025; 214(3): 242-50. https://doi.org/10.1097/JU.0000000000004589
  19. The NAMS 2020 GSM Position Statement Editorial Panel. The 2020 genitourinary syndrome of menopause position statement of the North American Menopause Society. Menopause. 2020; 27(9): 976-92. https://doi.org/10.1097/GME.0000000000001609
  20. Rueda C., Osorio A.M., Avellaneda A.C., Pinzуn C.E., Restrepo O.I. The efficacy and safety of estriol to treat vulvovaginal atrophy in postmenopausal women: a systematic literature review. Climacteric. 2017; 20(4): 321-30. https://doi.org/10.1080/13697137.2017.1329291
  21. Hirschberg A.L., Bitzer J., Cano A., Ceausu I., Chedraui P., Durmusoglu F. et al. Topical estrogens and non-hormonal preparations for postmenopausal vulvovaginal atrophy: An EMAS clinical guide. Maturitas. 2021; 148: 55-61. https://doi.org/10.1016/j.maturitas.2021.04.005
  22. Weidlinger S., Schmutz C., Janka H., Gruetter C., Stute P. Sustainability of vaginal estrogens for genitourinary syndrome of menopause - a systematic review. Climacteric. 2021; 24(6): 551-9. https://doi.org/10.1080/13697137.2021.1891218
  23. Matarazzo M.G., Sarpietro G., Fiorito D., Di Pasqua S., Ingrassano S., Panella M.M. et al. Intravaginal 6.5 mg prasterone administration in postmenopausal women with overactive bladder syndrome: A pilot study. Eur. J. Obstet. Gynecol. Reprod. Biol. 2021; 263: 67-71. https://doi.org/10.1016/j.ejogrb.2021.06.009
  24. Duarte P.R., Maroto Martín M.T., Mar Martín Moya M.D., Prados P.A. Quality of life analysis measured with the Cervantes 16 scale in treated menopausal women with genitourinary syndrome. J. Comp. Eff. Res. 2022; 11(18): 1365-74. https://doi.org/10.2217/cer-2022-0086.
  25. Labrie F. Intracrinology and menopause: the science describing the cell-specific intracellular formation of estrogens and androgens from DHEA and their strictly local action and inactivation in peripheral tissues. Menopause. 2019; 26(2):220-4. https://doi.org/10.1097/GME.0000000000001177
  26. Labrie F., Archer D.F., Koltun W., Vachon A., Young D., Frenette L. et al.; members of the VVA Prasterone Research Group. Efficacy of intravaginal dehydroepiandrosterone (DHEA) on moderate to severe dyspareunia and vaginal dryness, symptoms of vulvovaginal atrophy, and of the genitourinary syndrome of menopause. Menopause. 2018; 25(11): 1339-53. https://doi.org/10.1097/GME.0000000000001238
  27. Labrie F., Archer D.F., Martel C., Vaillancourt M., Montesino M. Combined data of intravaginal prasterone against vulvovaginal atrophy of menopause. Menopause. 2017; 24(11): 1246-56. https://doi.org/10.1097/GME.0000000000000910
  28. Cappola A.R., Auchus R.J., El-Hajj Fuleihan G., Handelsman D.J., Kalyani R.R., McClung M. et al. Hormones and aging: An Endocrine Society Scientific Statement. J. Clin. Endocrinol. Metab. 2023; 108(8): 1835-74. https://doi.org/10.1210/clinem/dgad225
  29. Объединенная позиция российских экспертов по вопросу клинического значения гиперандрогении у женщин в ранней постменопаузе. Акушерство и гинекология. 2025; 5: 201-6.
  30. Gluvic Z., Zaric B., Resanovic I., Obradovic M., Mitrovic A., Radak D. et al. Link between metabolic syndrome and insulin resistance. Curr. Vasc. Pharmacol. 2017; 15(1): 30-9. https://doi.org/10.2174/1570161114666161007164510
  31. Stefanska A., Bergmann K., Sypniewska G. Metabolic syndrome and menopause: pathophysiology, clinical and diagnostic significance. Adv. Clin. Chem. 2015; 72: 1-75. https://doi.org/10.1016/bs.acc.2015.07.001
  32. Hirschberg A.L. Hyperandrogenism and cardiometabolic risk in pre- and postmenopausal women-What is the evidence? J. Clin. Endocrinol. Metab. 2024; 109(5): 1202-13. https://doi.org/10.1210/clinem/dgad590
  33. Hirschberg A.L. Approach to investigation of hyperandrogenism in a postmenopausal woman. J. Clin. Endocrinol. Metab. 2023; 108(5): 1243-53. https://doi.org/10.1210/clinem/dgac673
  34. Frederiksen H., Johannsen T.H., Andersen S.E., Petersen J.H., Busch A.S., Ljubicic M.L. et al. Sex- and age-specific reference intervals of 16 steroid metabolites quantified simultaneously by LC-MS/MS in sera from 2458 healthy subjects aged 0 to 77 years. Clin. Chim. Acta. 2024; 562: 119852. https://doi.org/10.1016/j.cca.2024.119852
  35. Torréns J.I., Sutton-Tyrrell K., Zhao X., Matthews K., Brockwell S., Sowers M. et al. Relative androgen excess during the menopausal transition predicts incident metabolic syndrome in midlife women: study of Women's Health Across the Nation. Menopause. 2009; 16(2): 257-64. https://doi.org/10.1097/gme.0b013e318185e249
  36. Alemany M. The roles of androgens in humans: biology, metabolic regulation and health. Int. J. Mol. Sci. 2022; 23(19): 11952. https://doi.org/10.3390/ijms231911952
  37. Galmés-Pascual B.M., Martínez-Cignoni M.R., Morán-Costoya A., Bauza-Thorbrügge M., Sbert-Roig M., Valle A. et al. 17β-estradiol ameliorates lipotoxicity-induced hepatic mitochondrial oxidative stress and insulin resistance. Free Radic. Biol. Med. 2020; 150: 148-60. https://doi.org/10.1016/j.freeradbiomed.2020.02.016
  38. Nestler J.E., Jakubowicz D.J., de Vargas A.F., Brik C., Quintero N., Medina F. Insulin stimulates testosterone biosynthesis by human thecal cells from women with polycystic ovary syndrome by activating its own receptor and using inositolglycan mediators as the signal transduction system. J. Clin. Endocrinol. Metab. 1998; 83(6): 2001‐5. https://doi.org/10.1210/jcem.83.6.4886
  39. Xing C., Zhang J., Zhao H., He B. Effect of sex hormone-binding globulin on polycystic ovary syndrome: mechanisms, manifestations, genetics, and treatment. Int. J. Womens Health. 2022; 14: 91‐105. https://doi.org/10.2147/IJWH.S344542
  40. Dicker A., Rydén M., Näslund E., Muehlen I.E., Wirén M., Lafontan M. et al. Effect of testosterone on lipolysis in human pre-adipocytes from different fat depots. Diabetologia. 2004; 47(3): 420‐8. https://doi.org/10.1007/s00125-003-1324-0
  41. Zang H., Rydén M., Wåhlen K., Dahlman-Wright K., Arner P., Lindén Hirschberg A. Effects of testosterone and estrogen treatment on lipolysis signaling pathways in subcutaneous adipose tissue of postmenopausal women. Fertil. Steril. 2007; 88(1): 100-6. https://doi.org/10.1016/j.fertnstert.2006.11.088
  42. Grundy S.M. Metabolic syndrome: a multiplex cardiovascular risk factor. J. Clin. Endocrinol. Metab. 2007; 92(2): 399-404. https://doi.org/10.1210/jc.2006-0513
  43. Hu G.; DECODE Study Group. Gender difference in all-cause and cardiovascular mortality related to hyperglycaemia and newly-diagnosed diabetes. Diabetologia. 2003; 46(5): 608-17. https://doi.org/10.1007/s00125-003-1096-6
  44. Министерство здравоохранения Российской Федерации. Клинические рекомендации. Сахарный диабет 2 типа у взрослых. 2022. Доступно по: https://cr.minzdrav.gov.ru/preview-cr/290_2
  45. Zhang L., Bao L., Li Y., Wang C., Dong X., Abdulai T. et al. Age at menopause, body mass index, and risk of type 2 diabetes mellitus in postmenopausal Chinese women: The Henan Rural Cohort study. Nutr. Metab. Cardiovasc. Dis. 2020; 30(8): 1347-54. https://doi.org/10.1016/j.numecd.2020.04.003
  46. Opoku A.A., Abushama M., Konje J.C. Obesity and menopause. Best Pract. Res. Clin. Obstet. Gynaecol. 2023; 88: 102348. https://doi.org/10.1016/j.bpobgyn.2023.102348
  47. Vishram J.K.K., Borglykke A., Andreasen A.H., Jeppesen J., Ibsen H., Jørgensen T. et al. Impact of age and gender on the prevalence and prognostic importance of the metabolic syndrome and its components in Europeans. The MORGAM Prospective Cohort Project. PLoS One. 2014; 9(9): e107294. https://doi.org/10.1371/journal. pone.0107294
  48. Lizcano F., Guzmán G. Estrogen deficiency and the origin of obesity during menopause. Biomed. Res. Int. 2014; 2014: 757461. https://doi.org/10.1155/2014/757461
  49. Zhu J., Zhou Y., Jin B., Shu J. Role of estrogen in the regulation of central and peripheral energy homeostasis: from a menopausal perspective. Ther. Adv. Endocrinol. Metab. 2023; 14: 20420188231199359. https://doi.org/10.1177/20420188231199359
  50. Драпкина О.М., Концевая А.В., Калинина А.М., Авдеев С.Н., Агальцов М.В., Александрова Л.М. и др. Профилактика хронических неинфекционных заболеваний в Российской Федерации. Национальное руководство 2022. Кардиоваскулярная терапия и профилактика. 2022; 21(4): 5-232.
  51. Юренева С.В. Ожирение в период менопаузального перехода: как прервать негативные связи и предупредить последствия? Акушерство и гинекология. 2024; 11: 56-65.
  52. Chen G.C., Arthur R., Iyengar N.M., Kamensky V., Xue X., Wassertheil-Smoller S. et al. Association between regional body fat and cardiovascular disease risk among postmenopausal women with normal body mass index. Eur. Heart J. 2019; 40(34): 2849-55. https://doi.org/10.1093/eurheartj/ehz391
  53. Министерство здравоохранения Российской Федерации. Клинические рекомендации. Ожирение. 2024. Доступно по: https://cr.minzdrav.gov.ru/preview-cr/28_3
  54. Министерство здравоохранения Российской Федерации. Клинические рекомендации. Артериальная гипертензия у взрослых. 2024. Доступно по: https://cr.minzdrav.gov.ru/preview-cr/62
  55. Alberti K.G., Zimmet P., Shaw J.; IDF Epidemiology Task Force Consensus Group. The metabolic syndrome--a new worldwide definition. Lancet. 2005; 366(9491): 1059-62. https://doi.org/10.1016/S0140-6736(05)67402-8
  56. Wang J., Wu D., Guo H., Li M. Hyperandrogenemia and insulin resistance: The chief culprit of polycystic ovary syndrome. Life Sci. 2019; 236: 116940. https://doi.org/10.1016/j.lfs.2019.116940
  57. Cushman M., Kuller L.H., Prentice R., Rodabough R.J., Psaty B.M., Stafford R.S. et al. Estrogen plus progestin and risk of venous thrombosis. JAMA. 2004; 292(13): 1573-80. https://doi.org/10.1001/jama.292.13.1573
  58. Григорян О.Р., Андреева Е.Н. Ожирение и менопауза. В кн.: Трошина Е.А., Покусаева В.Н., Андреева Е.Н.; под ред. Мельниченко Г.А., Никифоровского Н.К. Ожирение у женщин. М.: Медицинское информационное агентство; 2017: 233-68. 
  59. Caprio M., Antelmi A., Chetrite G., Muscat A., Mammi C., Marzolla V. et al. Antiadipogenic effects of the mineralocorticoid receptor antagonist drospirenone: Potential implications for the treatment of metabolic syndrome. Endocrinology. 2011; 152(1): 113-25. https://doi.org/10.1210/en.2010-0674
  60. Дедов И.И., Шестакова М.В., Викулова О.К., Железнякова А.В., Исаков М.А. Эпидемиологические характеристики сахарного диабета в Российской Федерации: клинико-статистический анализ по данным регистра сахарного диабета на 01.01.2021. Сахарный диабет. 2021; 24(3): 204-21.
  61. Salpeter S.R., Walsh J.M., Ormiston T.M., Greyber E., Buckley N.S., Salpeter E.E. Meta-analysis: effect of hormone-replacement therapy on components of the metabolic syndrome in postmenopausal women. Diabetes Obes. Metab. 2006; 8(5): 538-54. https://doi.org/10.1111/j.1463-1326.2005.00545
  62. Schindler A.E., Campagnoli C., Druckmann R., Huber J., Pasqualini J.R., Schweppe K.W. et al. Classification and pharmacology of progestins. Maturitas. 2008; 61(1-2): 171-80. https://doi.org/10.1016/j.maturitas.2008.11.013.
  63. Mendoza N., Ramírez I., De La Viuda E., Coronado P., Baquedano L., Llaneza P. et al. Eligibility criteria for Menopausal Hormone Therapy (MHT): a position statement from a consortium of scientific societies for the use of MHT in women with medical conditions. MHT Eligibility Criteria Group. Maturitas. 2022; 166: 65-85. https://doi.org/10.1016/j.maturitas.2022.08.008
  64. De Filippis A., Ullah H., Baldi A., Dacrema M., Esposito C., Garzarella E.U. et al. Gastrointestinal disorders and metabolic syndrome: dysbiosis as a key link and common bioactive dietary components useful for their treatment. Int. J. Mol. Sci. 2020; 21(14): 4929. https://doi.org/10.3390/ijms21144929
  65. Zuvarox T., Belletieri C. Malabsorption syndromes. 2023 Jul 24. In: StatPearls
  66. Elkafas H., Walls M., Al-Hendy A., Ismail N. Gut and genital tract microbiomes: Dysbiosis and link to gynecological disorders. Front. Cell Infect. Microbiol. 2022; 12: 1059825. https://doi.org/10.3389/fcimb.2022.1059825
  67. Xie X., Song J., Wu Y., Li M., Guo W., Li S. et al. Study on gut microbiota and metabolomics in postmenopausal women. BMC Womens Health. 2024; 24(1): 608. https://doi.org/10.1186/s12905-024-03448-7
  68. The 2022 hormone therapy position statement of The North American Menopause Society. Menopause. 2022; 29(7): 767-94. https://doi.org/10.1097/GME.0000000000002028
  69. Kim J.E., Chang J.H., Jeong M.J., Choi J., Park J., Baek C. et al. A systematic review and meta-analysis of effects of menopausal hormone therapy on cardiovascular diseases. Sci. Rep. 2020; 10(1): 20631. https://doi.org/10.1038/s41598-020-77534-9
  70. Boardman H.M., Hartley L., Eisinga A., Main C., Roqué i Figuls M., Bonfill Cosp X. et al. Hormone therapy for preventing cardiovascular disease in post-menopausal women. Cochrane Database Syst. Rev. 2015; 2015(3): CD002229. https://doi.org/10.1002/14651858.CD002229.pub4
  71. Vinogradova Y., Coupland C., Hippisley-Cox J. Use of hormone re- placement therapy and risk of venous thromboembolism: nested case-control studies using the QResearch and CPRD databases. BMJ. 2019; 364: k4810. https://doi.org/10.1136/bmj.k4810
  72. Goldštajn M.Š., Mikuš M., Ferrari F.A., Bosco M., Uccella S., Noventa M. et al. Effects of transdermal versus oral hormone replacement therapy in postmenopause: a systematic review. Arch. Gynecol. Obstet. 2023; 307(6):1727-45. https://doi.org/10.1007/s00404-022-06647-5
  73. Kapoor E., Kling J.M., Lobo A.S., Faubion S.S. Menopausal hormone therapy in women with medical conditions. Best Pract. Res. Clin. Endocrinol. Metab. 2021; 35(6): 101578. https://doi.org/10.1016/j.beem.2021.101578
  74. Morris G., Talaulikar V. Hormone replacement therapy in women with history of thrombosis or a thrombophilia. Post Reprod. Health. 2023; 29(1): 33-41. https://doi.org/10.1177/20533691221148036
  75. Dinger J., Bardenheuer K., Heinemann K. Drospirenone plus es- tradiol and the risk of serious cardiovascular events in post-menopausal women. Climacteric. 2016; 19(4): 349-56. https://doi.org/10.1080/13697137.2016.1183624
  76. Sobel T.H., Shen W. Transdermal estrogen therapy in meno- pausal women at increased risk for thrombotic events: a scoping review. Menopause. 2022; 29(4): 483-90. https://doi.org/10.1097/ GME.0000000000001938
  77. Roetker N.S., MacLehose R.F., Hoogeveen R.C., Ballantyne C.M., Basu S., Cushman M. et al. Prospective study of endogenous hormones and incidence of venous thromboembolism: the atherosclerosis risk in communities study. Thromb. Haemost. 2018; 118(11): 1940-50. https://doi.org/10.1055/s-0038-1673613
  78. Tepper N.K., Whiteman M.K., Marchbanks P.A., James A.H., Curtis K.M. Progestin-only contraception and thromboembolism: A systematic review. Contraception. 2016; 94(6): 678-700. https://doi.org/10.1016/j.contraception.2016.04.014
  79. Mantha S., Karp R., Raghavan V., Terrin N., Bauer K.A., Zwicker J.I. Assessing the risk of venous thromboembolic events in women taking progestin-only contraception: a meta-analysis. BMJ. 2012; 345: e4944. https://doi.org/10.1136/bmj.e4944
  80. Nudy M., Chinchilli V.M., Foy A.J. A systematic review and meta-regression analysis to examine the ‘timing hypothesis’ of hormone replacement therapy on mortality, coronary heart disease, and stroke. Int. J. Cardiol. Heart Vasc. 2019; 22: 123-31. https://doi.org/10.1016/j.ijcha.2019.01.001
  81. Cho L., Kaunitz A.M., Faubion S.S., Hayes S.N., Lau E.S., Pristera N. et al. Rethinking menopausal hormone therapy: For whom, what, when, and how long? Circulation. 2023; 147(7): 597-610. https://doi.org/10.1161/ CIRCULATIONAHA.122.061559
  82. LaVasseur C., Neukam S., Kartika T., Samuelson Bannow B., Shatzel J., DeLoughery T.G. Hormonal therapies and venous thrombosis: Con- siderations for prevention and management. Res. Pract. Thromb. Haemost. 2022; 6(6): e12763. https://doi.org/10.1002/ rth2.12763
  83. Roach R.E., Lijfering W.M., van Hylckama Vlieg A., Helmerhorst F.M., Rosendaal F.R., Cannegieter S.C. The risk of venous thrombosis in in- dividuals with a history of superficial vein thrombosis and acquired venous thrombotic risk factors. Blood. 2013; 122(26): 4264-9. https://doi.org/10.1182/blood-2013-07-518159
  84. Straczek C., Oger E., Yon De Jonage-Canonico M.B., Plu-Bureau G., Conard J., Meyer G. et al. Prothrombotic mutations, hormone therapy, and venous thromboembolism among postmenopausal women: impact of the route of estrogen administration. Circulation. 2005; 112(22): 3495-500. https://doi.org/10.1161/CIRCULA- TIONAHA.105.565556
  85. Morris G., Talaulikar V. Hormone replacement therapy in women with history of thrombosis or a thrombophilia. Post Reprod. Health. 2023; 29(1): 33-41. https://doi.org/10.1177/20533691221148036
  86. Middeldorp S., Nieuwlaat R., Baumann Kreuziger L., Coppens M., Houghton D., James A.H. et al. American Society of Hematology 2023 guidelines for management of venous thromboembolism: thrombophilia testing. Blood Adv. 2023; 7(22): 7101-38. https://doi.org/10.1182/bloodadvances.2023010177
  87. Guyatt G.H., Akl E.A., Crowther M., Gutterman D.D., Schuьnemann H.J.; American College of Chest Physicians Antithrombotic Therapy and Prevention of Thrombosis Panel. Executive summary: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012; 141(2 Suppl): 7S-47S. https://doi.org/10.1378/chest.1412S3
  88. Hulley S., Grady D., Bush T., Furberg C., Herrington D., Riggs B. et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. JAMA. 1998; 280(7): 605-13. https://doi.org/10.1001/jama.280.7.605
  89. Yuk J.S., Kim G.S., Kim D.G., Byun Y.S., Kim M.H., Yoon S.H. et al. Association of menopausal hormone therapy with risk of cardiovascular disease in Korean women. Eur. J. Endocrinol. 2025; 192(2): 73-80. https://doi.org/10.1093/ejendo/lvae161
  90. Wassertheil-Smoller S., Hendrix S., Limacher M., Heiss G., Kooperberg C., Baird A. et al. Effect of estrogen plus progestin on stroke in postmenopausal women: the Women’s Health Initiative: a randomized trial. JAMA. 2003; 289(20): 2673-84. https://doi.org/10.1001/jama.289.20.2673
  91. Hendrix S.L., Wassertheil-Smoller S., Johnson K.C., Howard B.V., Kooperberg C., Rossouw J.E. et al. Effects of conjugated equine estrogen on stroke in the Women’s Health Initiative. Circulation. 2006; 113(20): 2425-34. https://doi.org/10.1161/CIRCULATIONAHA.105.594077
  92. Te West N.I.D., Day R.O., Hiley B., White C., Wright M., Moore K.H. Estriol serum levels in new and chronic users of vaginal estriol cream: A prospective observational study. Neurourol. Urodyn. 2020; 39(4): 1137-44. https://doi.org/10.1002/nau.24331
  93. Santen R.J., Mirkin S., Bernick B., Constantine G.D. Systemic estradiol levels with low-dose vaginal estrogens. Menopause. 2020; 27(3): 361-70. https://doi.org/10.1097/GME.0000000000001463
  94. Bhupathiraju S.N., Grodstein F., Stampfer M.J., Willett W.C., Crandall C.J., Shifren J.L. et al. Vaginal estrogen use and chronic disease risk in the Nurses’ Health Study. Menopause. 2019; 26(6): 603-10. https://doi.org/10.1097/GME.0000000000001284
  95. Crandall C.J., Hovey K.M., Andrews C.A., Chlebowski R.T., Stefanick M.L., Lane D.S. et al. Breast cancer, endometrial cancer, and cardiovascular events in participants who used vaginal estrogen in the Womens Health Initiative Observational Study. Menopause. 2018; 25(1): 11-20. https://doi.org/10.1097/GME.0000000000000956
  96. Орлова Я.А., Плисюк А.Г., Долгушин Г.О., Кириллова К.И., Михеев Р.К., Андреева Е.Н. Связь длительной менопаузальной гормональной терапии и показателей сосудистого и репликативного старения у женщин. Профилактическая медицина. 2023; 26(7): 96-102. 
  97. Draper M.W., Flowers D.E., Huster W.J., Neild J.A., Harper K.D., Arnaud C. A controlled trial of raloxifene (LY139481) HCl: Impact on bone turnover and serum lipid profile in healthy postmenopausal women. J. Bone Miner. Res. 2009; 11(6): 835-42. https://doi.org/10.1002/jbmr.5650110615
  98. Nie G., Yang X., Wang Y., Liang W., Li X., Luo Q. et al. The Effects of menopause hormone therapy on lipid profile in postmenopausal women: a systematic review and meta-analysis. Front. Pharmacol. 2022; 13: 850815. https://doi.org/10.3389/fphar.2022.850815
  99. Ежов М.В., Кухарчук В.В., Сергиенко И.В., Алиева А.С., Анциферов М.Б., Аншелес А.А. и др. Нарушения липидного обмена. Клинические рекомендации 2023. Российский кардиологический журнал. 2023; 28(5): 250-97. 
  100. Nordestgaard B.G., Chapman M.J., Ray K., Borén J., Andreotti F., Watts G.F. et al. Lipoprotein(a) as a cardiovascular risk factor: current status. Eur. Heart J. 2010; 31(23): 2844-53. https://doi.org/10.1093/eurheartj/ehq386
  101. Honigberg M.C., Trinder M., Natarajan P. Lipoprotein(a), menopausal hormone therapy, and risk of coronary heart disease in postmenopausal individuals. JAMA Cardiol. 2022; 7(5): 565-68. https://doi.org/10.1001/jamacardio.2022.0716
  102. Stevenson J.C., Chines A., Pan K., Ryan K.A., Mirkin S. A pooled analysis of the effects of conjugated estrogens/bazedoxifene on lipid parameters in postmenopausal women from the Selective Estrogens, Menopause, and Response to Therapy (SMART) Trials. J. Clin. Endocrinol. Metab. 2015; 100(6): 2329-38. https://doi.org/10.1210/jc.2014-2649
  103. Miller V.T., LaRosa J., Barnabei V., Kessler C., Levin G., Smith-Roth A. et al. Effects of estrogen or estrogen/ progestin regimens on heart disease risk factors in postmenopausal women: the Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. JAMA. 1995; 273(3): 199-208. https://doi.org/10.1001/jama.1995.03520270033028
  104. Binder E.F., Birge S.J., Kohrt W.M. Effects of endurance exercise and hormone replacement therapy on serum lipids in older women. J. Am. Geriatr. Soc. 1996; 44(3): 231-6. https://doi.org/10.1111/j.1532-5415.1996.tb00907.x
  105. Bunyavejchevin S., Limpaphayom K.K. The metabolic and bone density effects of continuous combined 17-beta estradiol and noresthisterone acetate treatments in Thai postmenopausal women: a double- blind placebo-controlled trial. J. Med. Assoc. Thai. 2001; 84(1): 45-53.
  106. Çayan F., Gen R., Akbay E., Dilek U., Dilek S. The effect of hormone therapy and tibolone on glucose and lipid metabolism in healthy postmenopausal women. Turkish Journal of Geriatrics. 2011; 14(1): 19-25. Available at: https://geriatri.dergisi.org/abstract. php?id=534
  107. Cheng G.J., Liu J.L., Zhang Q., Fan W., Ye H.F., Wang Z.Q. et al. Nylestriol replacement therapy in postmenopausal women. A three-year prospective study. Chin. Med. J. (Engl). 1993; 106(12): 911-6.
  108. Conard J., Basdevant A., Thomas J.L., Ochsenbein E., Denis C., Guyene T.T. et al. Cardiovascular risk factors and combined estrogen-progestin replacement therapy: a placebo-controlled study with nomegetrol acetate and estradiol. Fertil. Steril. 1995; 64(5): 957-62. https://doi.org/10.1016/S0015-0282(16)57909-6
  109. Conard J., Gompel A., Pelissier C., Mirabel C., Basdevant A. Fibrinogen and plasminogen modifications during oral estradiol replacement therapy. Fertil. Steril. 1997; 68(3): 449-53. https://doi.org/10.1016/S0015-0282(97)00220-3
  110. Davidson M.H., Maki K.C., Marx P., Maki A.C., Cyrowski M.S., Nanavati N. et al. Effects of continuous estrogen and estrogen-progestin replacement regimens on cardiovascular risk markers in postmenopausal women. Arch. Intern. Med. 2000; 160(21): 3315-25. https://doi.org/10.1001/archinte.160.21.3315
  111. Duvernoy C.S., Rose P.A., Kim H.M., Kehrer C., Brook R.D. Combined continuous ethinyl estradiol/norethindrone acetate does not improve forearm blood flow in postmenopausal women at risk for cardiovascular events: a pilot study. J. Womens Health (Larchmt). 2007; 16(7): 963-70. https://doi.org/10.1089/jwh.2006.0321
  112. Casanova G., Dos Reis A.M., Spritzer P.M. Low-dose oral or non-oral hormone therapy: effects on C-reactive protein and atrial natriuretic peptide in menopause. Climacteric. 2015; 18(1): 86-93. https://doi.org/10.3109/13697137.2014.940309
  113. Haase C.L., Tybjærg-Hansen A., Ali Qayyum A., Schou J., Nordestgaard B.G., Frikke-Schmidt R. LCAT, HDL cholesterol and ischemic cardiovascular disease: A Mendelian randomization study of hdl cholesterol in 54,500 individuals. J. Clin. Endocrinol. Metab. 2012; 97(2): E248-56. https://doi.org/10.1210/jc.2011-1846
  114. Lv C., Zhang W., Tan X., Shang X., Găman M.A., Salem H. et al. The effect of tibolone treatment on lipid profile in women: A systematic review and dose-response meta-analysis of randomized controlled trials. Pharmacol. Res. 2021; 169: 105612. https://doi.org/10.1016/j.phrs.2021.105612
  115. Anagnostis P., Galanis P., Chatzistergiou V., Stevenson J.C., Godsland I.F., Lambrinoudaki I. et al. The effect of hormone replacement therapy and tibolone on lipoprotein (a) concentrations in postmenopausal women: A systematic review and meta-analysis. Maturitas. 2017; 99: 27-36. https://doi.org/10.1016/j.maturitas.2017.02.009
  116. Falkeborn M., Persson I., Adami H.O., Bergstrom R., Eaker E., Lithell H. et al. The risk of acute myocardial infarction after oestrogen and oestrogen- progestogen replacement. Br. J. Obstet. Gynaecol. 1992; 99(10): 821-8. https://doi.org/10.1111/j.1471-0528.1992.tb14414.x
  117. Shufelt C.L., Manson J.E. Menopausal hormone therapy and cardiovascular disease: the role of formulation, dose, and route of delivery. J. Clin. Endocrinol. Metab. 2021; 106(5): 1245-54. https://doi.org/10.1210/clinem/dgab042
  118. Anagnostis P., Bitzer J., Cano A., Ceausu I., Chedraui P., Durmusoglu F. et al. Menopause symptom management in women with dyslipidemias: An EMAS clinical guide. Maturitas. 2020; 135: 82-8 https://doi.org/10.1016/j.maturitas.2020.03.007
  119. Wenger N.K., Lloyd-Jones D.M., Elkind M.S.V., Fonarow G.C., Warner J.J., Alger H.M. et al. Call to action for cardiovascular disease in women: epidemiology, awareness, access, and delivery of equitable health care: A Presidential Advisory from the American Heart Association. Circulation. 2022; 145(23): e1059-71. https://doi.org/10.1161/CIR.0000000000001071
  120. Vogel B., Acevedo M., Appelman Y., Bairey Merz C.N., Chieffo A., Figtree G.A. et al. The Lancet women and cardiovascular disease Commission: reducing the global burden by 2030. Lancet. 2021; 397(10292): 2385-438. https://doi.org/10.1016/S0140-6736(21)00684-X
  121. Reckelhoff J.F. Gender differences in hypertension Curr. Opin. Nephrol. Hypertens. 2018; 27: 176-81. https://doi.org/10.1097/ MNH.0000000000000404
  122. Cho L., Davis M., Elgendy I., Epps K., Lindley K.J., Mehta P.K. et al.; ACC CVD Womens Committee Members. Summary of Updated Recommendations for Primary Prevention of Cardiovascular Disease in Women: JACC State-of-the-Art Review. J. Am. Coll. Cardiol. 2020; 75(20): 2602-18. https://doi.org/10.1016/j.jacc.2020.03.060
  123. Gerdts E., Sudano I., Brouwers S., Borghi C., Bruno R.M., Ceconi C. et al. Sex differences in arterial hypertension. Eur. Heart J. 2022; 43(46): 4777-88. https://doi.org/10.1093/eurheartj/ehac470
  124. NCD Risk Factor Collaboration (NCD-RisC). Worldwide trends in hypertension prevalence and progress in treatment and control from 1990 to 2019: a pooled analysis of 1201 population-representative studies with 104 million participants. Lancet. 2021; 398(10304): 957-980. https://doi.org/10.1016/S0140-6736(21)01330-1
  125. O’Keeffe L.M., Simpkin A.J., Tilling K., Anderson E.L., Hughes A.D., Lawlor D.A. et al. Sex-specific trajectories of measures of cardiovascular health during childhood and adolescence: A prospective cohort study. Atherosclerosis. 2018; 278: 190-6. https://doi.org/10.1016/j.atherosclerosis.2018.09.030
  126. Ji H., Kim A., Ebinger J.E., Niiranen T.J., Claggett B.L., Bairey Merz C.N. et al. Sex differences in blood pressure trajectories over the life course. JAMA Cardiol. 2020; 5(3): 19-26. https://doi.org/10.1001/jamacardio.2019.5306
  127. Maas A., Rosano G., Cifkova R., Chieffo A., Van Dijken D., Hamoda H. et al. Cardiovascular health after menopause transition, pregnancy disorders, and other gynaecologic conditions: a consensus document from European cardiologists, gynaecologists, and endocrinologists. Eur. Heart J. 2021; 42(10): 967-84. https://doi.org/10.1093/eurheartj/ehaa1044
  128. El Khoudary S.R., Aggarwal B., Beckie T.M., Hodis H.N., Johnson A.E., Langer R.D. et al. Menopause transition and cardiovascular disease risk: implications for timing of early prevention: A Scientific Statement From the American Heart Association. Circulation. 2020; 142(25): e506-32. https://doi.org/10.1161/CIR.0000000000000912
  129. Biglia N., Cagnacci A., Gambacciani M., Lello S., Maffei S., Nappi R.E. Vasomotor symptoms in menopause: a biomarker of cardiovascular disease risk and other chronic diseases? Climacteric. 2017; 20(4): 306-12. https://doi.org/10.1080/13697137.2017.1315089
  130. Chapman N., Ching S.M., Konradi A.O., Nuyt A.M., Khan T., Twumasi-Ankrah B. et al. Arterial hypertension in women: state of the art and knowledge gaps. Hypertension. 2023; 80(6): 1140-9. https://doi.org/10.1161/HYPERTENSIONAHA.122.20448
  131. Coutinho T. Arterial stiffness and its clinical implications in women. Can. J. Cardiol. 2014; 30(7): 756-64. https://doi.org/10.1016/j.cjca.2014.03.020
  132. Picone D.S., Kodithuwakku V., Mayer C.C., Chapman N., Rehman S., Climie R.E. Sex differences in pressure and flow waveform physiology across the life course. J. Hypertens. 2022; 40(12): 2373-84. https://doi.org/10.1097/HJH.0000000000003283
  133. Mosca L., Benjamin E.J., Berra K., Bezanson J.L., Dolor R.J., Lloyd-Jones D.M. et al. Effectiveness-based guidelines for the prevention of cardiovascular disease in women-2011 Update: A Guideline from the American Heart Association. Circulation. 2011; 123(11): 1243-62. https://doi.org/10.1161/ CIR.0b013e31820faaf8
  134. Issa Z., Seely E.W., Rahme M., El-Hajj Fuleihan G. Effects of hormone ther apy on blood pressure. Menopause. 2015; 22(4): 456-68. https://doi.org/10.1097/GME.0000000000000322
  135. Mancia G., Kreutz R., Brunström M., Burnier M., Grassi G., Januszewicz A. et al. 2023 ESH Guidelines for the management of arterial hypertension The Task Force for the management of arterial hypertension of the European Society of Hypertension Endorsed by the International Society of Hypertension (ISH) and the European Renal Association (ERA). J. Hypertens. 2023; 41(12): 1874-2071. https://doi.org/10.1097/ HJH.0000000000003480
  136. Кобалава Ж.Д., Конради А.О., Недогода С.В., Шляхто Е.В., Арутюнов Г.П., Баранова Е.И. и др. Артериальная гипертензия у взрослых. Клинические рекомендации 2020. Российский кардиологический журнал. 2020; 25(3): 149-218. 
  137. Curb J.D., Prentice R.L., Bray P.F., Langer R.D., Van Horn L., Barnabei V.M. et al. Venous thrombosis and conjugated equine estrogen in women without a uterus. Arch. Intern. Med. 2006; 166(7): 772-80. https://doi.org/10.1001/archinte.166.7.772
  138. Blondon M., Wiggins K.L., Van Hylckama Vlieg A., McKnight B., Psaty B.M., Rice K.M. et al. Smoking, postmenopausal hormone therapy and the risk of venous thrombosis: a population-based, case-control study. Br. J. Haematol. 2013; 163(3): 418-20. https://doi.org/10.1111/bjh.12508
  139. Ruan X., Mueck A.O. Impact of smoking on estrogenic efficacy. Climacteric. 2015; 18(1): 38-46. https://doi.org/10.3109/13697137.2014.929106
  140. Li Y., Zhao D., Wang M., Sun J., Liu J., Qi Y. et al. Association of menopause with risk of carotid artery atherosclerosis. Maturitas. 2021; 143: 171-7. https://doi.org/10.1016/j.maturitas.2020.10.007
  141. Schreinlechner M., Noflatscher M., Reinstadler S.J., Sommer P., Lener D., Reiser E. et al. Early onset of menopause is associated with increased peripheral atherosclerotic plaque volume and progression. Atherosclerosis. 2020; 297: 25-31. https://doi.org/10.1016/j.atherosclerosis.2020.01.023
  142. Westendorp I., in’t Veld B.A., Grobbee D.E., Pols H., Meijer W.T., Hofman A. et al. Hormone replacement therapy and peripheral arterial disease: the Rotterdam study. Arch. Intern. Med. 2000; 160(16): 2498-502. https://doi.org/10.1001/archinte.160.16.2498
  143. Rockman C.B., Maldonado T.S., Jacobowitz G.R., Adelman M.A., Riles T.S. Hormone replacement therapy is associated with a decreased prevalence of peripheral arterial disease in postmenopausal women. Ann. Vasc. Surg. 2012; 26(3): 411-8. https://doi.org/10.1016/j.avsg.2011.10.012
  144. Hodis H.N., Mack W.J., Henderson V.W., Shoupe D., Budoff M.J., Hwang-Levine J. et al.; ELITE Research Group. Vascular effects of early versus late postmenopausal treatment with estradiol. N. Engl. J. Med. 2016; 374(13): 1221-31. https://doi.org/10.1056/NEJMoa1505241
  145. Chen I.J., Stanczyk F.Z., Sriprasert I., Karim R., Shoupe D., Kono N. et al. Sex steroid hormones and subclinical atherosclerosis progression in postmenopausal women. Eur. J. Endocrinol. 2025; 192(3): 248-56. https://doi.org/10.1093/ejendo/lvaf032
  146. Anagnostis P., Mikhailidis D.P., Blinc A., Jensterle M., Ježovnik M.K., Schernthaner G.H. et al. The effect of menopause and menopausal hormone therapy on the risk of peripheral artery disease. Curr. Vasc. Pharmacol. 2023; 21(5): 293-6. https://doi.org/10.2174/ 0115701611263345230919122907
  147. Hulley S., Grady D., Bush T., Furburg C., Herrington D., Riggs B. et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. JAMA. 1998; 280: 605-13. https://doi.org/10.1001/jama.280.7.605
  148. Grady D., Herrington D., Bittner V., Blumenthal R., Davidson M., Hlatky M. et al.; HERS Research Group. Cardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestin Replacement Study follow-up (HERS II). JAMA. 2002; 288(1): 49-57. https://doi.org/10.1001/jama.288.1.49
  149. Davies R.S., Vohra R.K., Bradbury A.W., Adam D.J. The impact of hormone replacement therapy on the pathophysiology of peripheral arterial disease. Eur. J. Vasc. Endovasc. Surg. 2007; 34(5): 569-75. https://doi.org/10.1016/j.ejvs.2007.06.002
  150. Поляков Д.C., Фомин И.В., Беленков Ю.Н., Мареев В.Ю., Агеев Ф.Т., Артемьева Е.Г. и др. Хроническая сердечная недостаточность в Российской Федерации: что изменилось за 20 лет наблюдения? Результаты исследования ЭПОХА-ХСН. Кардиология. 2021; 61(4): 4-14. 
  151. Mozaffarian D., Benjamin E.J., Go A.S., Arnett D.K., Blaha M.J., Cushman M. et al.; American Heart Association Statistics Committee; Stroke Statistics Subcommittee. Heart Disease and Stroke Statistics-2016 Update: A Report from the American Heart Association. Circulation. 2016; 133(4): e38-360. https://doi.org/10.1161/CIR.0000000000000350
  152. Appiah D., Schreiner P.J., Demerath E.W., Loehr L.R., Chang P.P., Folsom A.R. Association of age at menopause with incident heart failure: a prospective cohort study and meta-analysis. J. Am. Heart Assoc. 2016; 5(8): e003769. https://doi.org/10.1161/JAHA.116.003769
  153. Schierbeck L.L., Rejnmark L., Tofteng C.L., Stilgren L., Eiken P., Mosekilde L. et al. Effect of hormone replacement therapy on cardiovascular events in recently postmenopausal women: randomised trial. BMJ. 2012; 345: e6409. https://doi.org/10.1136/bmj.e6409
  154. Lindenfeld J., Ghali J.K., Krause-Steinrauf H.J., Khan S., Adams K., Goldman S. et al.; BEST Investigators. Hormone replacement therapy is associated with improved survival in women with advanced heart failure. J. Am. Coll. Cardiol. 2003; 42(7): 1238-45. https://doi.org/10.1016/S0735-1097(03)00938-0
  155. Arayici M.E., Kilic M.E., Yilmaz M.B. The impact of hormone replacement therapy on the risk of heart failure in postmenopausal women: a meta-analysis of clinical and observational studies. Pharmacoepidemiol. Drug Saf. 2024; 33(10): e70029. https://doi.org/10.1002/pds.70029
  156. Liu L., Klein L., Eaton C., Panjrath G., Martin L.W., Chae C.U. et al. Menopausal hormone therapy and risks of first hospitalized heart failure and its subtypes during the intervention and extended post-intervention follow-up of the Women’s Health Initiative Randomized Trials. J. Card. Fail. 2020; 26(1): 2-12. https://doi.org/10.1016/j.cardfail.2019.09.006
  157. Baik S.H., Baye F., McDonald C.J. Use of menopausal hormone therapy beyond age 65 years and its effects on women's health outcomes by types, routes, and doses. Menopause. 2024; 31(5): 363-71. https://doi.org/10.1097/GME.0000000000002335
  158. Kirchhof P., Benussi S., Kotecha D., Ahlsson A., Atar D., Casadei B. et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur. Heart J. 2016; 37(38): 2893-962. https://doi.org/10.1093/eurheartj/ehw210
  159. Fang M.C., Singer D.E., Chang Y., Hylek E.M., Henault L.E., Jensvold N.G. et al. Gender differences in the risk of ischemic stroke and peripheral embolism in atrial fibrillation: the AnTicoagulation and Risk factors In Atrial fibrillation (ATRIA) Study. Circulation. 2005; 112(12): 1687-91. https://doi.org/10.1161/CIRCULATIONAHA.105.553438
  160. Dagres N., Nieuwlaat R., Vardas P.E., Andresen D., Levy S., Cobbe S. et al. Gender-related differences in presentation, treatment, and outcome of patients with atrial fibrillation in Europe. J. Am. Coll. Cardiol. 2007; 49(5): 572-7. https://doi.org/10.1016/j.jacc.2006.10.047
  161. Van Gelder I.C., Rienstra M., Bunting K.V., Casado-Arroyo R., Caso V., Crijns H.J.G.M. et al.; ESC Scientific Document Group. 2024 ESC Guidelines for the management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS). Eur. Heart J. 2024; 45(36): 3314-414. https://doi.org/10.1093/eurheartj/ehae176
  162. Lee J., Kim Y., Park H., Kim C., Cho S., Kim J. Clinical impact of hormone replacement therapy on atrial fibrillation in postmenopausal women: a nationwide cohort study. J. Clin. Med. 2021; 10(23): 5497. https://doi.org/10.3390/jcm10235497
  163. Antoun I., Layton G.R., Abdelrazik A., Eldesouky M., Zakkar M., Somani R. et al. The pathophysiology of sex differences in stroke risk and prevention in atrial fibrillation: a comprehensive review. Medicina (Kaunas). 2025; 61(4): 649. https://doi.org/10.3390/medicina61040649
  164. Magnussen C., Niiranen T.J., Ojeda F.M., Gianfagna F., Blankenberg S., Njolstad I. et al. Sex differences and similarities in atrial fibrillation epidemiology, risk factors, and mortality in community cohorts: results from the BiomarCaRE Consortium (Biomarker for Cardiovascular Risk Assessment in Europe). Circulation. 2017; 136(17): 1588-97. https://doi.org/10.1161/CIRCULATIONAHA.117.028981
  165. Perez M.V., Wang P.J., Larson J.C., Virnig B.A., Cochrane B., Curb J.D. et al. Effects of postmenopausal hormone therapy on incident atrial fibrillation: the Women’s Health Initiative randomized controlled trials. Circ. Arrhythm. Electrophysiol. 2012; 5(6): 1108-16. https://doi.org/10.1161/CIRCEP.112.972224
  166. Tsai W.C., Haung Y.B., Kuo H.F., Tang W.H., Hsu P.C., Su H.M. et al. Hormone replacement therapy and risk of atrial fibrillation in Taiwanese menopause women: A nationwide cohort study. Sci. Rep. 2016; 6(1): 24132. https://doi.org/10.1038/srep24132
  167. Wong J.A., Rexrode K.M., Sandhu R.K., Moorthy M.V., Conen D., Albert C.M. Menopausal age, postmenopausal hormone therapy and incident atrial fibrillation. Heart. 2017; 103(24): 1954-61. https://doi.org/10.1136/heartjnl-2016-311002
  168. Lee J., Kim Y., Park H., Kim C., Cho S., Kim J. Clinical Impact of hormone replacement therapy on atrial fibrillation in postmenopausal women: a nationwide cohort study. J. Clin. Med. 2021; 10(23): 5497. https://doi.org/10.3390/jcm10235497
  169. Fleury M.A., Clavel M.A. Sex and race differences in the pathophysiology, diagnosis, treatment, and outcomes of valvular heart diseases. Can. J. Cardiol. 2021; 37(7): 980-91. https://doi.org/10.1016/j.cjca.2021.02.003
  170. Rodriguez-Arias J.J., García-Álvarez A. Sex differences in pulmonary hypertension. Front. Aging. 2021; 2: 727558. https://doi.org/10.3389/fragi.2021.727558
  171. Hye T., Dwivedi P., Li W., Lahm T., Nozik-Grayck E., Stenmark K.R. et al. Newer insights into the pathobiological and pharmacological basis of the sex disparity in patients with pulmonary arterial hypertension. Am. J. Physiol. Lung Cell Mol. Physiol. 2021; 320(6): L1025-L1037. https://doi.org/10.1152/ajplung.00559.2020
  172. Liu A., Schreier D., Tian L., Eickhoff J.C., Wang Z., Hacker T.A. et al. Direct and indirect protection of right ventricular function by estrogen in an experimental model of pulmonary arterial hypertension. Am. J. Physiol. Heart Circ. Physiol. 2014; 307(3): H273-83. https://doi.org/10.1152/ajpheart.00758.2013
  173. Badlam J.B., Badesch D., Brittain E., Cordell S., Ding T., Fox K. et al. Sex hormone exposure and reproductive factors in pulmonary arterial hypertension: a case-control study. Pulm. Circ. 2020; 10(1): 2045894020908786. https://doi.org/10.1177/2045894020908786
  174. Министерство здравоохранения Российской Федерации. Клинические рекомендации. Мигрень. 2024. Доступно по: https://cr.minzdrav.gov.ru/preview-cr/295_4
  175. Nappi R.E., Tiranini L., Sacco S., De Matteis E., De Icco R., Tassorelli C. Role of estrogens in menstrual migraine. Cells. 2022; 11(8): 1355. https://doi.org/10.3390/cells11081355
  176. Lee S.R., Cho M.K., Cho Y.J., Chun S., Hong S.H., Hwang K.R. et al.; Academic Committee of the Korean Society of Menopause. The 2020 Menopausal Hormone Therapy Guidelines. J. Menopausal Med. 2020; 26(2): 69-98. https://doi.org/10.6118/jmm.20000
  177. Australasian Menopause Society. Migraine headaches, menopause and MHT/HRT. Available at: https://menopause.org.au/hp/information-sheets/migraine-headaches-menopause-and-mht-hrt
  178. British Menopause Society. Migraine and HRT. Available at: https://thebms.org.uk/publications/tools-for-clinicians/migraine-and-hrt/
  179. Garvey W.T., Garber A.J., Mechanick J.I., Bray G.A., Dagogo-Jack S., Einhorn D. et al.; The Aace Obesity Scientific Committee. American association of clinical endocrinologists and american college of endocrinology position statement on the 2014 advanced framework for a new diagnosis of obesity as a chronic disease. Endocr. Pract. 2014; 20(9): 977-89. https://doi.org/10.4158/EP14280.PS
  180. Сметник А.А., Иванов И.А., Ермакова Е.И., Табеева Г.И. Особенности использования менопаузальной гормональной терапии в России: результаты масштабного опроса женщин в пери- и постменопаузе. Акушерство и гинекология. 2025; 8: 196-208.
  181. Сухих Г.Т., Серов В.Н., Шляхто Е.В., Дедов И.И., Арутюнов Г.П., Ткачева О.Н., Сметник А.А., Сучков И.А., Баранов И.И., Шестакова М.В., Мельниченко Г.А., Васюкова О.В., Шереметьева Е.В., Андреева Е.Н., Шестакова Е.А., Орлова Я.А., Виллевальде С.В., Иртюга О.Б., Сергиенко И.В., Явелов И.С., Козиолова Н.А., Ермакова Е.И., Дудинская Е.Н. Менопаузальная гормональная терапия у пациенток с сердечно-сосудистыми и метаболическими заболеваниями: междисциплинарный дельфийский консенсус среди российских гинекологов, кардиологов, эндокринологов, геронтологов и гериатров, флебологов, клиничес­ких фармакологов. Терапевтический архив.